Radiogenomics and Radioproteomics

Djekidel, Mehdi

doi:10.4172/2167-7964.1000115

Cited by 6 publications

(6 citation statements)

References 23 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 However, a brain tumor biopsy not only is costly 7 but also poses risks inherent to an invasive procedure. 8,9 An imaging based characterization also presents other advantages, 10 such as permitting interrogation of tumor heterogeneity characteristics and an assessment of tumor pathophysiology. More recently, it has also been suggested that GBMs harbor multiple cell subpopulations; 11 hence, an imaging based examination can also provide an insight into the molecular programs driving the disease.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of tumor‐derived MRI‐texture features for discrimination of molecular subtypes and prediction of 12‐month survival status in glioblastoma

et al. 2015

View full text Add to dashboard Cite

The authors evaluated the performance of five types of texture features in predicting GBM molecular subtypes and 12-month survival status. The authors' results show that texture features are predictive of molecular subtypes and survival status in GBM. These results indicate the feasibility of using tumor-derived imaging features to guide genomically informed interventions without the need for invasive biopsies.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of tumor‐derived MRI‐texture features for discrimination of molecular subtypes and prediction of 12‐month survival status in glioblastoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It can be expected that with these advances, multidimensional studies in breast cancer will be undertaken, combining multiple qualitative and quantitative imaging parameters not only with genomic but also transcriptomic, proteomic, and metabolomic data. Ideally, such studies will devise meaningful imaging biomarkers to achieve the ultimate goal of precision medicine in breast cancer (150).…”

Section: Future Perspectivesmentioning

confidence: 99%

Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment

et al. 2018

View full text Add to dashboard Cite

Precision medicine is medicine optimized to the genotypic and phenotypic characteristics of an individual and, when present, his or her disease. It has a host of targets, including genes and their transcripts, proteins, and metabolites. Studying precision medicine involves a systems biology approach that integrates mathematical modeling and biology genomics, transcriptomics, proteomics, and metabolomics. Moreover, precision medicine must consider not only the relatively static genetic codes of individuals, but also the dynamic and heterogeneous genetic codes of cancers. Thus, precision medicine relies not only on discovering identifiable targets for treatment and surveillance modification, but also on reliable, noninvasive methods of identifying changes in these targets over time. Imaging via radiomics and radiogenomics is poised for a central role. Radiomics, which extracts large volumes of quantitative data from digital images and amalgamates these together with clinical and patient data into searchable shared databases, potentiates radiogenomics, which is the combination of genetic and radiomic data. Radiogenomics may provide voxel-by-voxel genetic information for a complete, heterogeneous tumor or, in the setting of metastatic disease, set of tumors and thereby guide tailored therapy. Radiogenomics may also quantify lesion characteristics, to better differentiate between benign and malignant entities, and patient characteristics, to better stratify patients according to risk for disease, thereby allowing for more precise imaging and screening. This report provides an overview of precision medicine and discusses radiogenomics specifically in breast cancer. RSNA, 2018.

show abstract

“…Another future direction is the incorporation of the whole spectrum of “omics” technologies, ie, transcriptomics, proteomics, and metabolomics in radio‐“omics” research. It can be expected that the integration of multiple “omics” technologies—genomics, transcriptomics, proteomics, metabolomics—with advanced imaging techniques will further open up new avenues in the diagnosis and treatment of diseases, with initial data being promising …”

Section: Future Directionsmentioning

confidence: 99%

“…It can be expected that the integration of multiple "omics" technologies-genomics, transcriptomics, proteomics, metabolomics-with advanced imaging techniques will further open up new avenues in the diagnosis and treatment of diseases, with initial data being promising. 2,9,[151][152][153] Radio-"omics" studies mandate the availability of large datasets, patient characteristics, and, in particular, standardization of imaging techniques to provide meaningful and clinically applicable results. It has to be noted that to date there often is a substantial inter-and intrainstitutional heterogeneity in datasets stemming from differences in hardware, sequences, and postprocessing approaches.…”

Section: Future Directionsmentioning

confidence: 99%